SCHEMBL1079330

SCHEMBL1079330

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1cc2cnc(N)nc2c(-c2cccnc2)c1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 10/20 0.62
KDR P35968 9/20 0.62
MAPK14 Q16539 8/20 0.62
TEK Q02763 5/20 0.62
JAK3 P52333 4/20 0.62
KIT P10721 3/20 0.54
CSF1R P07333 3/20 0.54
DDR2 Q16832 6/20 0.52
DDR1 Q08345 5/20 0.52
ABL1 P00519 4/20 0.52
BCR P11274 4/20 0.52
BRAF P15056 4/20 0.51
PDGFRB P09619 3/20 0.50
ESYT2 A0FGR8 2/20 0.49
NBAS A2RRP1 2/20 0.49
CNOT1 A5YKK6 2/20 0.49
TBKBP1 A7MCY6 2/20 0.49
AGPS O00116 2/20 0.49
MYO1F O00160 2/20 0.49
SNAP23 O00161 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1079570 0.92 KDR (0.64) LCKKDRMAPK14TEKJAK3
SCHEMBL1149256 0.92 LCK (0.64) LCKKDRMAPK14TEKJAK3
SCHEMBL1149384 0.91 LCK (0.64) LCKKDRMAPK14TEKJAK3
SCHEMBL1077337 0.91 KDR (0.59) LCKKDRMAPK14TEKJAK3
SCHEMBL1149176 0.90 LCK (0.63) LCKKDRMAPK14TEKJAK3
SCHEMBL1148998 0.90 LCK (0.67) LCKKDRMAPK14TEKJAK3
SCHEMBL1149446 0.90 LCK (0.67) LCKKDRMAPK14TEKJAK3
SCHEMBL14715721 0.90 KDR (0.64) LCKKDRMAPK14TEKJAK3
SCHEMBL1078899 0.90 LCK (0.64) LCKKDRMAPK14TEKJAK3
SCHEMBL1148921 0.90 LCK (0.48) LCKKDRMAPK14TEKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 LCK 3187/4885KDR 896/4885MAPK14 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.